Key facts
- Khartis Therapeutics’s last known valuation is $74.0M.
- It has raised $44.5M; the latest was Early Stage VC ($40.0M) in Nov 2024.
- Notable investors include Foresite Capital, Lilly Asia Ventures, Nextech Invest.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Khartis Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Khartis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Khartis Therapeutics
Developer of oral therapies designed for patients with immune-mediated and chronic diseases. The company's drug discovery team focuses on creating impactful small molecule treatments through scientific innovation and translational research, enabling the advancement of meaningful therapies that address significant unmet medical needs.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Website
- khartis.com/
- Ownership
- Privately Held (backing)
Khartis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Khartis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Khartis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.